Archive
1250 articles, sorted by publication time.
Researchers repeatedly induced liver tumors in mice with four different genetic backgrounds and found that inherited genetic differences influence which driver mutations cancer cells select, whether they duplicate their entire genome, and which early cell populations survive.
The new system can semi-automatically mark kidney and spleen dimensions, and its performance was validated using existing images from 150 people. However, it assists with the measurement workflow rather than providing automated diagnosis, and evidence for abnormal cases remains limited.
A new model trained on more than 870,000 image–report pairs breaks predictions down into clinically recognizable radiological concepts; testing on data from the United States, Spain, and Vietnam shows that transparency can also serve as a tool for identifying bias and correcting models.
The new company will advance an mGluR modulator that has completed a small Phase 2 trial into a multinational Phase 2b study; the asset and clinical capabilities have been reorganized, but efficacy still needs to be demonstrated in a larger, more clearly designed study.
Two studies have turned CRISPR from a tool for precise gene rewriting into a cell-clearance system activated by oncogenic RNA; it can already distinguish abnormalities involving HPV, KRAS, EGFR, and TP53, but delivery and systemic safety remain major barriers to therapeutic use.
The FDA has accepted the first ISTAND letter of intent for a computer-simulation tool designed to predict drug-induced liver injury, opening a new pathway for small-molecule drug safety assessment; however, the model has not yet been qualified and cannot replace existing tests.
The cash-and-stock transaction brings cryopreservation media and cell-processing tools into Repligen’s portfolio; as cell therapies move toward commercialization, competition is expanding beyond bioreactors to whether cells can be safely preserved, transported, and used again.
The PRMT5 and SOS1 inhibitors will be advanced into global trials by the newly established Kaveri; Lupin retains more than 80% ownership, but there are still insufficient details to assess efficacy, safety, and follow-on funding.
Using liver biopsy as a common reference, the LITMUS study compared multiple blood- and imaging-based tools. The results showed that serum markers performed better in identifying high-risk steatohepatitis, while elastography led in detecting advanced fibrosis and cirrhosis—but no single test could address every clinical question.
A Phase 3 trial in adolescents showed that oral tinlarebant not only slowed retinal lesion growth, but also tended to stabilize an autofluorescence signal associated with the accumulation of toxic substances; however, its visual benefit, long-term safety, and the outcome of the FDA review remain to be clarified.
A 300-person, multicenter randomized trial showed that Retina4IRD increased specialists’ top-five gene diagnosis accuracy from 67.3% to 88.5%. Its role is not to replace sequencing, but to provide more focused guidance before costly and complex genetic testing.
Studies in mice and lung cancer specimens indicate that complement C3 produced by tumor fibroblasts can prevent immunosuppressive myeloid cells from entering tumors and is associated with a better anti-PD-1 response; C3 in the blood, however, does not have the same effect.